Recent FDA approval of two blood tests that flag Alzheimer’s years before symptoms marks the most visible breakthrough in a field long stalled by failed drugs. The disease, identified by Alois Alzheimer in 1906, now affects over 7 million Americans, most over 65, and can incubate for two decades. Early detection could finally give clinicians a foothold.

The National Institutes of Health now pours roughly $4 billion annually into Alzheimer’s and dementia research, triple the level a decade ago and second only to cancer spending. Most of that money fuels a single amyloid‑centric hypothesis, yet investigators like Charles Piller—author of *Doctored*— argue the approach yields no disease‑modifying drugs. Piller’s reporting suggests systemic fraud may have redirected resources away from alternative mechanisms.

Neurologist Matthew Schrag at Vanderbilt argues vascular health, diet and cholesterol may drive plaque formation, a view he’s pursued since a 2006 rabbit study linking cholesterol‑rich diets to iron‑beta‑amyloid deposits. By shifting focus from amyloid alone to blood‑vessel pathology, researchers hope to uncover therapeutic angles that have eluded decades of trials. The episode asserts broader biological insight, not just amyloid clearance, is essential for progress.